| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 2008, p. 1520-1522, Vol. 46, No. 4
0095-1137/08/$08.00+0 doi:10.1128/JCM.02238-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom,1 Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand,2 Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, United Kingdom,3 Sappasithiprasong Hospital, Ubon Ratchathani 34000, Thailand,4 School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510080, People's Republic of China,5 Clinical Microbiology Laboratory, Guangzhou First Municipal People's Hospital, Guangzhou 510080, People's Republic of China6
Received 20 November 2007/ Returned for modification 15 January 2008/ Accepted 22 January 2008
We describe and validate a novel PCR assay to detect the pandemic hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) lineage ST 239. Results based on previously uncharacterized isolates from a hospital in northeast Thailand support the view that at least 90% of HA-MRSA isolates in mainland Asia correspond to ST 239 or close relatives.
Published ahead of print on 30 January 2008.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|